Cyteir Therapeutics Inc is a biotechnology business based in the US. Cyteir Therapeutics shares (CYT) are listed on the NASDAQ and all prices are listed in US Dollars. Cyteir Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.04 |
|---|---|
| 52-week range | $1.56 - $23.10 |
| 50-day moving average | $2.30 |
| 200-day moving average | $8.82 |
| Wall St. target price | $13.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.76 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.04 from 2022-07-01
| 1 week (2022-06-24) | 8.96% |
|---|---|
| 1 month (2022-06-02) | 54.31% |
| 3 months (2022-04-01) | -26.39% |
| 6 months (2021-12-31) | -73.26% |
| 1 year (2021-07-02) | -84.32% |
|---|---|
| 2 years (2020-06-28) | N/A |
| 3 years (2019-06-28) | N/A |
| 5 years (2017-06-28) | N/A |
| Gross profit TTM | $-16,591,000 |
|---|---|
| Return on assets TTM | -22.4% |
| Return on equity TTM | -38.06% |
| Profit margin | 0% |
| Book value | $4.95 |
| Market capitalisation | $98.8 million |
TTM: trailing 12 months
We're not expecting Cyteir Therapeutics to pay a dividend over the next 12 months.
Cyteir Therapeutics's shares were split on a 2:1 basis on 17 September 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cyteir Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cyteir Therapeutics shares which in turn could have impacted Cyteir Therapeutics's share price.
Cyteir Therapeutics, Inc. , a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts. .
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.